A multicenter phase II study of sepantronium bromide (YM155) plus rituximab in patients with relapsed aggressive B-cell Non-Hodgkin lymphoma

Inhibitor of Apoptosis (IAP) proteins in hematological malignancies: molecular mechanisms and therapeutic opportunities

(2014) S Fulda   LEUKEMIA

Survivin expression promotes VEGF-induced tumor angiogenesis via PI3K/Akt enhanced β-catenin/Tcf-Lef dependent transcription

(2014) Jaime G Fernández et al.   Molecular Cancer

A multicentre, phase II trial of ofatumumab monotherapy in relapsed/progressive diffuse large B-cell lymphoma

(2013) Bertrand Coiffier et al.   BRITISH JOURNAL OF HAEMATOLOGY

Morphological classification of the myelodysplastic syndromes: how much more education of diagnosticians is necessary?

(2013) J. M. Bennett   HAEMATOLOGICA

Multicenter Phase II Study of Bendamustine Plus Rituximab in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

(2013) Ken Ohmachi et al.   JOURNAL OF CLINICAL ONCOLOGY

Oral lenalidomide with rituximab in relapsed or refractory diffuse large cell, follicular and transformed lymphoma: a phase II clinical trial

(2013) M Wang et al.   LEUKEMIA

Abstract 2749: YM155, a small molecule survivin suppressant, sensitizes human B-cell non-Hodgkin lymphoma to rituximab-induced apoptosis

(2012) Naoki Kaneko et al.   CANCER RESEARCH

A phase II study of the survivin suppressant YM155 in patients with refractory diffuse large B-cell lymphoma

(2011) Bruce D. Cheson et al.   CANCER

Antitumor effects of YM155, a novel survivin suppressant, against human aggressive non-Hodgkin lymphoma

(2011) Aya Kita et al.   LEUKEMIA RESEARCH

Broad spectrum and potent antitumor activities of YM155, a novel small-molecule survivin suppressant, in a wide variety of human cancer cell lines and xenograft models

(2010) Takahito Nakahara et al.   CANCER SCIENCE

Characterization of Human Organic Cation Transporter 1 (OCT1/SLC22A1)- and OCT2 (SLC22A2)-Mediated Transport of 1-(2-Methoxyethyl)-2-methyl-4,9-dioxo-3-(pyrazin-2-ylmethyl)- 4,9-dihydro-1H-naphtho[2,3-d]imidazolium Bromide (YM155 Monobromide), a Novel Small Molecule Survivin Suppressant

(2009) T. Minematsu et al.   DRUG METABOLISM AND DISPOSITION

Transcriptional regulation of survivin by c-Myc in BCR/ABL-transformed cells: implications in anti-leukaemic strategy

(2008) Zhi Hong Fang et al.   JOURNAL OF CELLULAR AND MOLECULAR MEDICINE

Phase I and Pharmacokinetic Study of YM155, a Small-Molecule Inhibitor of Survivin

(2008) Anthony W. Tolcher et al.   JOURNAL OF CLINICAL ONCOLOGY

Rituximab improves the treatment results of DHAP-VIM-DHAP and ASCT in relapsed/progressive aggressive CD20+ NHL: a prospective randomized HOVON trial

(2007) E. Vellenga et al.   BLOOD